An abnormal neurological examination does not diagnose dementia. It usually leads to a broader evaluation for alternative or mixed causes, followed by laboratory tests and brain imaging. A neurological examination checks for signs that brain or nervous-system function may be abnormal. Its findings help clinicians decide whether memory or thinking problems could involve stroke, Parkinsonism, hydrocephalus, a tumor, or another disorder.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does an abnormal result mean?
- Completing the first-line assessment
- Which laboratory tests come next?
- MRI or CT brain imaging
- When specialist evaluation should be expedited
- Choosing targeted tests instead of ordering everything
What does an abnormal result mean?
An abnormal finding is a clue, not a final answer. It may point toward a condition other than dementia or suggest that more than one process is affecting the brain. For example, examination findings may raise concern about vascular injury, Parkinsonism, or another neurological disorder.
The Alzheimer's Association's diagnostic guidance explains that the examination helps identify conditions affecting memory and thinking. The meaning depends on the person's symptoms, daily function, risks, history, and other examination findings. No single sign or cognitive score should be interpreted alone.
Completing the first-line assessment
The clinician should perform a dementia-focused neurological and mental-status examination. A validated cognitive assessment should also measure areas of thinking that may be affected.
History provides essential context. The clinician should review: Informant input can reveal changes that a brief office visit misses. Medication effects, depression, and other contributors may resemble or worsen cognitive impairment.
- When the symptoms began and how quickly they changed
- Medical and psychiatric conditions
- Prescription drugs, over-the-counter medicines, and supplements
- Family history
- Changes in work, household tasks, finances, driving, or self-care
Which laboratory tests come next?
For nearly everyone with a confirmed cognitive-behavioral syndrome, the Alzheimer's Association DETeCD-ADRD guideline recommends Tier 1 laboratory testing. These tests look for common medical conditions that may contribute to impairment. The recommended group includes: Abnormal laboratory results may explain part of the person's difficulties, but they still require interpretation alongside symptoms, function, and neurological findings.
- Complete blood count
- Metabolic panel
- Thyroid-stimulating hormone
- Vitamin B12
- Homocysteine
MRI or CT brain imaging
Structural brain imaging generally follows the initial assessment. A noncontrast MRI is preferred because it can show atrophy, infarcts, white-matter disease, microhemorrhages, hydrocephalus, and mass lesions.
A noncontrast CT is the recommended alternative when MRI is unavailable or contraindicated. Imaging can identify structural clues, but its findings do not replace the clinical history, cognitive assessment, or examination.
When specialist evaluation should be expedited
Atypical neurological findings or an uncertain examination may require prompt specialist review. Early-onset symptoms and rapidly progressive decline also support expedited referral under the Alzheimer's Association specialty guideline.
Depending on the unresolved question, the clinician may refer the person to neurology, geriatrics, geriatric psychiatry, or neuropsychology. Bringing a medication list, symptom timeline, prior test results, and an informed family member can make that evaluation more useful.
Choosing targeted tests instead of ordering everything
If first-line testing does not resolve the cause, clinicians can select additional tests based on the person's clinical findings, psychiatric history, and risks. Options include neuropsychological testing, sleep studies, cerebrospinal-fluid biomarkers, PET, EEG, or vascular imaging. Blood biomarkers may assist an Alzheimer's workup in specialized care.
However, the FDA's Lumipulse clearance notice limits that plasma test to symptomatic adults aged 55 or older. The test is not intended for screening or as a stand-alone diagnosis. False-positive and false-negative results remain possible, so clinicians must interpret it within the full evaluation.
